Merck and AstraZeneca's Lynparza (Olaparib) Receive NICE Recommendation for Maintenance Treatment of BRCA-Mutated Cancers
Shots:
- NICE has recommended Merck and AstraZeneca's PARP inhibitor Lynparza as a maintenance treatment for relapsed platinum-sensitive ovarian, fallopian tube, or peritoneal cancer patients in England whose cancers harbor BRCA1 or BRCA2 mutations and who have received two prior courses of Pt-based CT
- The recommendation was based on the results from the P-III trial (SOLO-2) & showed that Lynparza can significantly delay disease progression and improved OS in BRCA1/2-mutated ovarian cancer patients
- Lynparza was approved in the US & EU for the treatment of advanced ovarian cancer patients with BRCA1/2 mutations after 1L CT in 2018 & 2019, respectively
Ref: Pharmiweb | Image: Merck
Related News:- AstraZeneca Reports P-III Trial (DUO-E) Results of Imfinzi (durvalumab) + Lynparza (olaparib) for Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
